Drugs that contain Daridorexant Hydrochloride

1. List of Quviviq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9732075 IDORSIA Benzimidazole-proline derivatives
Jun, 2033

(10 years from now)

US9790208 IDORSIA Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(11 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10023560 IDORSIA Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 7, 2027

NCE-1 date: 2026-04-07

Market Authorisation Date: 07 April, 2022

Treatment: Treatment of insomnia

Dosage: TABLET;ORAL

More Information on Dosage

QUVIVIQ family patents

7

United States

4

Korea, Republic of

4

European Union

3

Singapore

3

IB

3

Taiwan, Province of China

3

EA

3

Lithuania

3

Hungary

2

Portugal

2

Malaysia

2

Spain

2

Croatia

2

New Zealand

2

Norway

2

Philippines

2

Mexico

2

Morocco

2

China

2

Hong Kong

2

South Africa

2

Canada

2

Japan

2

Cyprus

2

Slovenia

2

Ukraine

2

Israel

2

Poland

2

Chile

2

Australia

2

Denmark

1

Brazil

1

Argentina

1

Saudi Arabia

1

Netherlands

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in